Amy Liu

Mubadala Capital was established in 2011, and in 2017, we became one of the first sovereign wealth-affiliated alternative asset managers to manage third-party capital on behalf of institutional investors across the globe. In just over a decade, we have built a new type of investment firm, one designed to evolve alongside the shifting alternative investment landscape and meet the needs of investors of all types, including private wealth. Our ability to navigate complexity and unlock value positions us ahead of market trends, while our commitment to building enduring businesses enables long-term, sustainable returns. Learn more at www.mubadalacapital.ae

Mubadala Capital was established in 2011, and in 2017, we became one of the first sovereign wealth-affiliated alternative asset managers to manage third-party capital on behalf of institutional investors across the globe. In just over a decade, we have built a new type of investment firm, one designed to evolve alongside the shifting alternative investment landscape and meet the needs of investors of all types, including private wealth. Our ability to navigate complexity and unlock value positions us ahead of market trends, while our commitment to building enduring businesses enables long-term, sustainable returns. Learn more at www.mubadalacapital.ae

BridgeBio finds, develops, and delivers breakthrough medicines for genetic diseases. Millions worldwide are afflicted with genetic diseases, but small patient populations and industry reluctance to conduct early-stage development means that for many, treatments have not been forthcoming. We are committed to bridging this gap: between business case and scientific possibility, between patient and hope. BridgeBio creates a bridge from remarkable advancements in genetic science to patients with unmet needs via the entrepreneurial engine required to make life-changing medicines as rapidly as possible. BridgeBio is committed to developing leaders as well as drugs. We are looking for individuals whose passion for creating life-changing medicines will inspire hands-on engagement and the dogged pursuit of novel solutions in the face of adversity.

Evercore (NYSE: EVR) is a premier global independent investment banking advisory firm. We are dedicated to helping our clients achieve superior results through trusted independent and innovative advice on matters of strategic and financial significance to boards of directors, management teams and shareholders, including mergers and acquisitions, strategic shareholder advisory, restructurings, and capital structure. Evercore also assists clients in raising public and private capital and delivers equity research and equity sales and agency trading execution, in addition to providing wealth and investment management services to high net worth and institutional investors. Founded in 1995, the Firm is headquartered in New York and maintains offices and affiliate offices in major financial centers in North America, Europe, South America, the Middle East and Asia. For more information, please visit www.evercore.com. Investment Banking - Corporate Advisory - Restructuring Advisory - Strategic Shareholder Advisory - Capital Markets Advisory - Evercore ISI - Private Funds Group - Private Capital Advisory Investment Management - Institutional Asset Management • Evercore Casa de Bolsa - Wealth Management • Evercore Wealth Management